Abstract
这项研究旨在确定全身性红斑狼疮(SLE)相关肺动脉高压(PAH)患者的长期临床结局和预后因素。
A multicentre prospective cohort of SLE-associated PAH was established. Baseline and follow-up records were collected. The primary end-point was death. The secondary exploratory end-point was treatment goal achievement (TGA), defined as an integrated outcome.
In total, 310 patients were enrolled from 14 PAH centres. The 1-, 3- and 5-year survival rates were 92.1%, 84.8% and 72.9%, respectively. The 1-, 3- and 5-year TGA rates were 31.5%, 53.6% and 62.7%, respectively. Baseline serositis, 6-min walking distance >380 m and cardiac index ≥2.5 L·min-1·m-2were identified as independent prognostic factors of TGA. Patients with baseline serositis were more likely to reach TGA after intensive immunosuppressive therapy. TGA was identified as a positive predictor of survival in patients with SLE-associated PAH.
TGA与长期生存有关,后者支持与SLE相关的PAH中的靶标策略。基线心脏功能预测了与SLE相关的PAH患者的生存和治疗目标实现。基线时血清炎的患者倾向于受益于强化免疫抑制疗法,并具有更好的临床结局。
Abstract
大型多中心队列研究新报道了SLE相关PAH的长期预后http://ow.ly/fras30mnaza
脚注
2019年2月14日在线发布;重新发布2019年2月28日,以纠正标签的错误图4C。
本文具有可用的补充材料www.qdcxjkg.com
作者贡献:概念和设计:J。,W。分析和解释:J。起草重要智力内容的手稿:J。Qian,M。Li,X。Zhang,X。Zeng。
下面的调查人员合作者the CSTAR-PAH study: C. Huang, X. Yang, D. Xu (rheumatology), Y. Liu, X. Guo, H. Wang, J. Lai (cardiology), Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences; N. Zhang, K. Yang, Y. Liu (rheumatology), S. Dong (cardiology), Tianjin Medical University General Hospital; Y. Lei, Y. Feng (rheumatology), Guangdong General Hospital; Y. Li, Y. Zhou (rheumatology), Xiangya Hospital, Central South University; Q. Wang (rheumatology), The First Affiliated Hospital of Nanjing Medical University; J. Jia, Q. Han (rheumatology), Xijing Hospital, Fourth Military Medical University; L. Guo, J. Chen (rheumatology), Ren Ji Hospital, Shanghai Jiao Tong University; Y. Zhang, Y. Liu (rheumatology), Beijing Chao-Yang Hospital, Capital Medical University; H. Xu (rheumatology), The First Central Hospital, Tianjin; Y. Sun (rheumatology): The Second Affiliated Hospital of Harbin Medical University; Y. Hao, Y. Fan (rheumatology), Peking University First Hospital; Q. Shu, Y. Wang (rheumatology), Qilu Hospital of Shandong University; Z. Lin (rheumatology), The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou; P. Qing (rheumatology), West China Hospital, Sichuan University.
Conflict of interest: J. Qian has nothing to disclose.
Conflict of interest: M. Li has nothing to disclose.
Conflict of interest: X. Zhang has nothing to disclose.
Conflict of interest: Q. Wang has nothing to disclose.
利益冲突:J。Zhao没有什么可披露的。
Conflict of interest: Z. Tian has nothing to disclose.
利益冲突:W。Wei无话可说。
利益冲突:X. Zuo没有什么可披露的。
利益冲突:张先生无话可说。
利益冲突:朱没有什么可披露的。
利益冲突:S。Ye没有什么可披露的。
利益冲突:W。Zhang没有什么可披露的。
利益冲突:Zheng没有什么可披露的。
利益冲突:W。Qi没有什么可披露的。
利益冲突:Y. Li没有什么可披露的。
利益冲突:Z. Zhang没有什么可披露的。
利益冲突:F。丁没有什么可披露的。
Conflict of interest: J. Gu has nothing to disclose.
利益冲突:刘Y.没有什么可披露的。
利益冲突:Y. Wang没有什么可披露的。
利益冲突:X. Zeng没有什么可披露的。
Support statement: This work was supported by the Chinese National Key Research R&D Program (grant numbers 2017YFC0907601, 2017YFC0907602, 2017YFC0907603, 2008BAI59B02) and the Chinese National High Technology Research and Development Program, Ministry of Science and Technology (grant number 2012AA02A513). Funding information for this article has been deposited with theCrossRef资助人注册表。
- 已收到2018年1月13日。
- 公认2018年11月12日。
- 复制right ©ERS 2019